Furthermore, these data provide support for the use of the FKBPL biomarker as a prognostic aid to patient management in early-stage ER+, LN-, Her2- breast cancer, which could be easily and cheaply incorporated alongside these standard biomarkers. The gene discussed is ERBB2; the disease is breast carcinoma.